1974
Jan Lilja, laboratory engineer, and Sven-Erik Nilsson, computer expert, of the Kristianstad Hospital Clinical Laboratory begin outlining an improved method for measuring hemoglobin.
1977
The soundness of the method and the feasibility of microcuvette production are proven.
1979
A license agreement with pharmaceutical company Leo is signed. Toward the end of the year, Lilja and Nilsson move into Leo's premises.
1982
Leo begins selling and distributing the first hemoglobin photometers.
1986
The hemoglobin system is successfully introduced on the US market. Turnover rises almost 80%.
1987
Leo is purchased by Pharmacia.
1988
Leo Diagnostics is bought out by the management and HemoCue AB is formed.
1990
Acquisition of US Distributor - HemoCue Inc. is founded.
1991
The glucose system, based on the same principles as the hemoglobin system, is introduced to the market.
1992
HemoCue finds a new owner: Mallinckrodt Inc of Saint Louis, Missouri, USA.
1995
The first HemoCue Academy takes place in Norrköping, Sweden.
1999
HemoCue is acquired by EQT, a private equity group in northern Europe. Annual turnover exceeds $40 million.
A new system, HemoCue® Plasma/Low Hb System, is introduced. The system is used for determination of low hemoglobin levels in plasma, serum and aqueous solutions.
2000
HemoCue® Donor Hb Checker, a system for measuring hemoglobin in blood donors, is introduced.
2001
The HemoCue 201 System for glucose is introduced.
By introducing a Urine Albumin analyzer for detecting microalbuminuria, HemoCue enters yet another significant testing area.
2002
The HemoCue 201 System for glucose is followed by a HemoCue® 201+ System for both glucose and hemoglobin making it possible to store test and QC results in the analyzer.
2003
HemoCue makes extensive investments in production technology, R&D, Sales and Marketing. Acquisition of Biotest. Distribution agreements with McKesson and PSS.
2004
HemoCue® Data Management Systems for glucose and hemoglobin are launched in Europe.
2005
Market introduction of HemoCue® Home Glucose.
2006
Market introduction of HemoCue® Albumin 201, HemoCue® Hb 301 and HemoCue® Glucose 201 RT.
2007
HemoCue is acquired by Quest Diagnostics.
2008
Market introduction of HemoCue® WBC, a system for determination of total white blood cell count. HemoCue® Albumin 201 System receives first FDA CLIA waiver in diagnostics industry for quantitative point-of-care test for microalbuminuria.
2010
HemoCue® WBC DIFF is introduced. A system that provides a quantitative determination of white blood cells with a five part differential count of neutrophils, lymfocytes, monocytes, eosinphils and basophils. The same year, we also launch two additional systems with room temperature microcuvette storage - the HemoCue® 201 RT and HemoCue 201 RT DM System.
2012
Another member to the diabetes portfolio is added with the launch of HemoCue® HbA1c 501 System. The new system is a fast, easy and reliable point-of-care system for hemoglobin A1c tests. It is a fully automated HbA1c POCT that provides reliable results at the point of care for efficient diabetes care.
2013
HemoCue is acquired by Radiometer Medical Aps, a Danaher company, in April 2013. Additional company information about Danaher and Radiometer is available on below links:
www.danaher.com
www.radiometer.com
2016
HemoCue® HealthTrender Anemia is launched. It is a solution that assists you in the fight against anemia. It provides immediate insight through real time data to the program manager for instant review and monitoring of anemia programs.
2017
We celebrate our 35th Anniversary at our headquarter in Ängelholm, Sweden. Our colleagues working at HemoCue offices around the world join us in the celebration.
2019
Beginning of January, we announce launch of our innovative HemoCue® Hb 801 System - the latest addition to our hemoglobin portfolio. The analyzer provides lab-accurate results in less than one second and features a unique "Let-go-grip" for easier handling. In February we receive 510(k) clearance from the US Food and Drug Administration (USFDA) and the product is launched on the US market.